AXLAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 12月 2023 @ 05:59):

Stats
本日の出来高	6 782.00
平均出来高	54 521.00
時価総額	1.18M
EPS	$0 ( 2024-03-28 )
次の収益日	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0220
ATR14	$0.625 (155.90%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-01	Koziel Margaret	Sell	679	Common Stock
2023-02-17	Koziel Margaret	Buy	70 000	Stock Option (Right to Buy)
2023-02-17	Hinshaw William	Buy	275 000	Stock Option (Right to Buy)
2023-02-17	Fehlner Paul	Buy	70 000	Stock Option (Right to Buy)
2023-02-10	Fehlner Paul	Buy	5 221	Common Stock

INSIDER POWER
99.86
Last 92 transactions
Buy: 44 458 855 \| Sell: 477 523

ボリューム相関

長: 0.47 (neutral)

短: 0.41 (neutral)

Signal:(20.847) Neutral

Axcella Health Inc 相関

10 最も正の相関
SEED	0.947
DZSI	0.941
POTX	0.94
INO	0.937
VIVE	0.933
RKDA	0.927
CHB	0.926
KRKR	0.926
PRPO	0.925
AQB	0.925

10 最も負の相関
MPRA	-0.943
NCAC	-0.941
APXI	-0.936
VMGA	-0.93
SCRM	-0.927
ALSA	-0.927
ZING	-0.926
TRON	-0.926
ARTEU	-0.924
ADAL	-0.921

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Axcella Health Inc 相関 - 通貨/商品

-0.05
( neutral )

-0.33
( neutral )

-0.21
( neutral )

-0.27
( neutral )

0.91
( very strong )

0.19
( neutral )

Axcella Health Inc 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.520

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-1.520

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.700

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.780

Financial Reports:

No articles found.

Axcella Health Inc

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

リアルタイムの更新： Axcella Health Inc [AXLA]

Upcoming Earnings Alert